维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

共被期刊论文引用了1次 您的检索式：您选中1篇文献正在查看引证文献汇总

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	The clinical value of BALP on diagnosis and treatment of osteoporosis in postmenopausal women显示文摘Objective: To investigate the changes of bone-specific alkaline phosphatase(BALP) in postmenopausal women, analyze the relationship between BALP and bone mineral density, and study the effects of treatment with risedronate on BALP. Methods: In this study, 243 women who were all at least 1 year past natural menopause were divided into two groups according to WHO standards. Group I was 100 osteopenic patients aged from 43 to 85 (mean age, 61.2 years). Group II was 143 osteoporotic patients aged from 45 to 80(mean age, 62.6 years). Bone mineral density(BMD) was measured by dual-energy X-ray absorptiometry (DEXA) and bone-specific alkaline phosphatase(BALP) was tested among all the patients. All the osteoporotic patients received 1-year Risedronate treatment. BALP was tested again after 3 months treatment of Risedronate for osteoporotic patients and BMD was measured after 1-year treatment. All data were processed by the application of statistical package SAS for windows V.6.12. Results: BALP was greater in the osteoporotic patients as compared with the osteopenic patients (P < 0.05). There was also a significant difference of BALP in the patients before and after treatment of risedronate(P < 0.05). BALP was greater in the patients who were less than 5 years past a natural menopause as compared with those who were more than 5 years past a natural menopause(P < 0.05). There was no significant difference of BALP in the patients who were more than 10 years past a natural menopause. Risedronate decreased serum BALP significantly. Logistic regression analyses showed that 3-month percentage decrease in BALP was profoundly associated with the 1-year percentage increase in BMD(r = 0.696, P < 0.01). Conclusion: BALP can predict the response in bone mass during Risedronate treatment in postmenopausal women and identify those noncompliant patients. 3-month percentage change in serum BALP was significantly correlated with the increase of BMD. Serum BALP can play a role in the monitoring of risedronate-treated postmenopausal women with osteoporosis, but it is poor to predict the treatment effects on an individual level.	Weiguo Li Hua Lin Yong Qiu Yongmei Zhang Xin Chen	2006	Journal of Nanjing Medical University2006，20，6：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费